Tonix Pharmaceuticals, a biopharmaceutical company with a diverse research portfolio, will participate in the World Vaccine Congress Washington 2025, presenting an oral presentation and leading a panel discussion from April 22-24 in Washington, D.C.
The conference provides a significant platform for Tonix to showcase its extensive work in pharmaceutical development, particularly its innovative approaches to addressing complex medical challenges. The company's current research spans multiple critical areas, including central nervous system disorders, infectious diseases, and pain management.
A key focus of Tonix's ongoing research is the potential submission of a New Drug Application to the U.S. Food and Drug Administration for TNX-102 SL, a product candidate for fibromyalgia management. The medication has already completed two statistically significant phase 3 studies and received Fast Track designation, signaling its potential importance in treating this challenging condition.
Additionally, Tonix has recently secured a significant contract from the U.S. Department of Defense's Defense Threat Reduction Agency worth up to $34 million over five years. This contract aims to develop TNX-4200, small molecule broad-spectrum antiviral agents designed to improve medical readiness for military personnel in biological threat environments.
The company's comprehensive development portfolio extends beyond pain management, encompassing critical research in central nervous system disorders, immunology, and infectious diseases. Notable projects include TNX-1300, a biologic in Phase 2 development for cocaine intoxication, and TNX-1500, a humanized monoclonal antibody targeting potential organ transplant rejection and autoimmune diseases.
Tonix's strategic approach to pharmaceutical research, coupled with its state-of-the-art infectious disease research facility in Frederick, Maryland, positions the company as a significant contributor to advancing medical solutions for complex health challenges.
